Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

  • Kobialka, Piotr
  • Sabata, Helena
  • Vilalta, Odena
  • Gouveia, Leonor
  • Angulo-Urarte, Ana
  • Muixí, Laia
  • Zanoncello, Jasmina
  • Muñoz-Aznar, Oscar
  • Olaciregui, Nagore G.
  • Fanlo, Lucía
  • Esteve-Codina, Anna
  • Lavarino, Cinzia
  • Javierre, Biola M.
  • Celis-Passini, Veronica Paola
  • Rovira, Carlota
  • López-Fernández, Susana
  • Baselga, Eulàlia
  • Mora, Jaume
  • Castillo, Sandra D.
  • Graupera, Mariona
Low-flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3caH1047R activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K-driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations., The research leading to these results has received funding by the Spanish Ministry of Science and Innovation MICINN (PID2020-116184RB-I00 /AEI/10.13038/501100011033). M.G. laboratory is supported by the research grants SAF2017-89116R-P (FEDER/EU) from MCIU (Spain) co-funded by European Regional Developmental Fund (ERDF), a Way to Build Europe and PID2020-116184RB-I00 from MCEI; PTEN RESEARCH Foundation (IJC-21-001); la Caixa Banking Foundation (LCF/PR/PR16/51110035 and LCF/PR/HR19/52160023; also to E.B. and J.M.); by la Asociación Española contra el Cancer (AECC)-Grupos Traslacionales (GCTRA18006CARR); by la Fundación BBVA (Ayuda Fundación BBVA a Equipos de Investigación Científica 2019); World Cancer Research (21-0159). The computations and data handling were enabled by resources in projects SNIC 2019/30-26 and SNIC 2019/8-129, provided by the Swedish National Infrastructure for Computing (SNIC) at UPPMAX, partially funded by the Swedish Research Council through grant agreement no. 2018-05973. Personal support was from Marie-Curie ITN Actions (P.K. and J.Z.) grant agreement 675392. L.G. is funded by the Swedish Research Council (2018-06591). S.D.C. is a recipient of a fellowship from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No 749731. S.D.C. is currently funded by la Caixa Banking Foundation Junior Leader project (LCF/BQ/PR20/11770002). E.B. is funded by the Agencia Estatal de Investigación (Proyectos de investigación en salud PI20/00102).
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility

  • Angulo Urarte, Ana
  • Casado, Pedro
  • Castillo, Sandra D.
  • Kobialka, Piotr
  • Kotini, Maria Paraskevi
  • Figueiredo, Ana Raquel Martins
  • Castel Morales, Pau
  • Rajeeve, Vinothini
  • Milà Guasch, Maria
  • Millán, Jaime
  • Wiesner, Cora
  • Serra, Helena
  • Muixi, Laura
  • Casanovas i Casanovas, Oriol
  • Viñals Canals, Francesc
  • Affolter, Markus
  • Gerhardt, Holger
  • Huveneers, Stephan
  • Belting, Heinz-Georg
  • Cutillas, Pedro R.
  • Graupera i Garcia-Milà, Mariona
Angiogenesis is a dynamic process relying on endothelial cell rearrangements within vascular tubes, yet the underlying mechanisms and functional relevance are poorly understood. Here we show that PI3Kα regulates endothelial cell rearrangements using a combination of a PI3Kα-selective inhibitor and endothelial-specific genetic deletion to abrogate PI3Kα activity during vessel development. Quantitative phosphoproteomics together with detailed cell biology analyses in vivo and in vitro reveal that PI3K signalling prevents NUAK1-dependent phosphorylation of the myosin phosphatase targeting-1 (MYPT1) protein, thereby allowing myosin light chain phosphatase (MLCP) activity and ultimately downregulating actomyosin contractility. Decreased PI3K activity enhances actomyosin contractility and impairs junctional remodelling and stabilization. This leads to overstretched endothelial cells that fail to anastomose properly and form aberrant superimposed layers within the vasculature. Our findings define the PI3K/NUAK1/MYPT1/MLCP axis as a critical pathway to regulate actomyosin contractility in endothelial cells, supporting vascular patterning and expansion through the control of cell rearrangement.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation

  • Martínez Corral, Inés
  • Zhang, Yan
  • Petkova, Milena
  • Ortsäter, Henrik
  • Sjöberg, Sofie
  • Castillo, Sandra D.
  • Brouillard, Pascal
  • Libbrecht, Louis
  • Saur, Dieter
  • Graupera i Garcia-Milà, Mariona
  • Alitalo, Kari
  • Boon, Laurence
  • Vikkula, Miikka
  • Mäkinen, Taija
Lymphatic malformations (LMs) are debilitating vascular anomalies presenting with large cysts (macrocystic) or lesions that infiltrate tissues (microcystic). Cellular mechanisms underlying LM pathology are poorly understood. Here we show that the somatic PIK3CAH1047R mutation, resulting in constitutive activation of the p110α PI3K, underlies both macrocystic and microcystic LMs in human. Using a mouse model of PIK3CAH1047R-driven LM, we demonstrate that both types of malformations arise due to lymphatic endothelial cell (LEC)-autonomous defects, with the developmental timing of p110α activation determining the LM subtype. In the postnatal vasculature, PIK3CAH1047R promotes LEC migration and lymphatic hypersprouting, leading to microcystic LMs that grow progressively in a vascular endothelial growth factor C (VEGF-C)-dependent manner. Combined inhibition of VEGF-C and the PI3K downstream target mTOR using Rapamycin, but neither treatment alone, promotes regression of lesions. The best therapeutic outcome for LM is thus achieved by co-inhibition of the upstream VEGF-C/VEGFR3 and the downstream PI3K/mTOR pathways.
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

PIK3CA mutations in vascular malformations

  • Castillo, Sandra D.
  • Baselga Torres, Eulalia
  • Graupera i Garcia-Milà, Mariona
Purpose of the review: Recently, it has been discovered that a subset of vascular malformations, of the lymphatic and venous type, are caused by oncogenic mutations in the PIK3CA gene. Now, efforts have been focused in the understanding of the molecular and cellular consequences of these mutations and the opportunities for novel targeted therapies for these diseases. Recent findings: Here, we review the latest findings in the biology of oncogenic PIK3CA mutations in the pathogenesis of vascular malformations. We focus on the recent development of in vitro and in vivo tools for the study of PIK3CA-mutant vascular malformations with special interest in preclinical models for drug testing. Also, we review the latest advances in PI3K inhibitors in the clinic and their repurposing for the treatment of lymphatic malformations (LMs) and venous malformations (VMs). Summary: Oncogenic mutations on PIK3CA causing LMs and VMs are also frequently found in epithelial cancer. Thus, fundamental research done in the cancer field during the past decades might be applied to the understanding of LMs and VMs. Likewise, repurposing PI3K pathway inhibitors that are currently in cancer clinical trials can be used as a novel strategy for the treatment of these diseases. Here, we also open a debate for the consideration of LMs and VMs as developmental tumours.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

  • Kobialka, Piotr
  • Sabata, Helena
  • Vilalta, Odena
  • Gouveia, Leonor
  • Angulo-Urarte, Ana
  • Muixí, Laia
  • Zanoncello, Jasmina
  • Muñoz-Aznar, Oscar
  • Olaciregui, Nagore G.
  • Fanlo, Lucía
  • Esteve-Codina, Anna
  • Lavarino, Cinzia
  • Javierre, Biola M.
  • Celis-Passini, Veronica Paola
  • Rovira, Carlota
  • López-Fernández, Susana
  • Baselga, Eulàlia
  • Mora, Jaume
  • Castillo, Sandra D.
  • Graupera, Mariona
Low-flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3caH1047R activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K-driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations., The research leading to these results has received funding by the Spanish Ministry of Science and Innovation MICINN (PID2020-116184RB-I00 /AEI/10.13038/501100011033). M.G. laboratory is supported by the research grants SAF2017-89116R-P (FEDER/EU) from MCIU (Spain) co-funded by European Regional Developmental Fund (ERDF), a Way to Build Europe and PID2020-116184RB-I00 from MCEI; PTEN RESEARCH Foundation (IJC-21-001); la Caixa Banking Foundation (LCF/PR/PR16/51110035 and LCF/PR/HR19/52160023; also to E.B. and J.M.); by la Asociación Española contra el Cancer (AECC)-Grupos Traslacionales (GCTRA18006CARR); by la Fundación BBVA (Ayuda Fundación BBVA a Equipos de Investigación Científica 2019); World Cancer Research (21-0159). The computations and data handling were enabled by resources in projects SNIC 2019/30-26 and SNIC 2019/8-129, provided by the Swedish National Infrastructure for Computing (SNIC) at UPPMAX, partially funded by the Swedish Research Council through grant agreement no. 2018-05973. Personal support was from Marie-Curie ITN Actions (P.K. and J.Z.) grant agreement 675392. L.G. is funded by the Swedish Research Council (2018-06591). S.D.C. is a recipient of a fellowship from the European Union's Horizon 2020 Research and Innovation Programme under the Marie Sklodowska-Curie grant agreement No 749731. S.D.C. is currently funded by la Caixa Banking Foundation Junior Leader project (LCF/BQ/PR20/11770002). E.B. is funded by the Agencia Estatal de Investigación (Proyectos de investigación en salud PI20/00102).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Blockade of VEGF-C signaling inhibits lymphatic malformations driven by oncogenic PIK3CA mutation

  • Martínez Corral, Inés
  • Zhang, Yan
  • Petkova, Milena
  • Ortsäter, Henrik
  • Sjöberg, Sofie
  • Castillo, Sandra D.
  • Brouillard, Pascal
  • Libbrecht, Louis
  • Saur, Dieter
  • Graupera i Garcia-Milà, Mariona
  • Alitalo, Kari
  • Boon, Laurence
  • Vikkula, Miikka
  • Mäkinen, Taija
Lymphatic malformations (LMs) are debilitating vascular anomalies presenting with large cysts (macrocystic) or lesions that infiltrate tissues (microcystic). Cellular mechanisms underlying LM pathology are poorly understood. Here we show that the somatic PIK3CAH1047R mutation, resulting in constitutive activation of the p110α PI3K, underlies both macrocystic and microcystic LMs in human. Using a mouse model of PIK3CAH1047R-driven LM, we demonstrate that both types of malformations arise due to lymphatic endothelial cell (LEC)-autonomous defects, with the developmental timing of p110α activation determining the LM subtype. In the postnatal vasculature, PIK3CAH1047R promotes LEC migration and lymphatic hypersprouting, leading to microcystic LMs that grow progressively in a vascular endothelial growth factor C (VEGF-C)-dependent manner. Combined inhibition of VEGF-C and the PI3K downstream target mTOR using Rapamycin, but neither treatment alone, promotes regression of lesions. The best therapeutic outcome for LM is thus achieved by co-inhibition of the upstream VEGF-C/VEGFR3 and the downstream PI3K/mTOR pathways.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility

  • Angulo Urarte, Ana
  • Casado, Pedro
  • Castillo, Sandra D.
  • Kobialka, Piotr
  • Kotini, Maria Paraskevi
  • Figueiredo, Ana Raquel Martins
  • Castel Morales, Pau
  • Rajeeve, Vinothini
  • Milà Guasch, Maria
  • Millán, Jaime
  • Wiesner, Cora
  • Serra, Helena
  • Muixi, Laura
  • Casanovas i Casanovas, Oriol
  • Viñals Canals, Francesc
  • Affolter, Markus
  • Gerhardt, Holger
  • Huveneers, Stephan
  • Belting, Heinz-Georg
  • Cutillas, Pedro R.
  • Graupera i Garcia-Milà, Mariona
Angiogenesis is a dynamic process relying on endothelial cell rearrangements within vascular tubes, yet the underlying mechanisms and functional relevance are poorly understood. Here we show that PI3Kα regulates endothelial cell rearrangements using a combination of a PI3Kα-selective inhibitor and endothelial-specific genetic deletion to abrogate PI3Kα activity during vessel development. Quantitative phosphoproteomics together with detailed cell biology analyses in vivo and in vitro reveal that PI3K signalling prevents NUAK1-dependent phosphorylation of the myosin phosphatase targeting-1 (MYPT1) protein, thereby allowing myosin light chain phosphatase (MLCP) activity and ultimately downregulating actomyosin contractility. Decreased PI3K activity enhances actomyosin contractility and impairs junctional remodelling and stabilization. This leads to overstretched endothelial cells that fail to anastomose properly and form aberrant superimposed layers within the vasculature. Our findings define the PI3K/NUAK1/MYPT1/MLCP axis as a critical pathway to regulate actomyosin contractility in endothelial cells, supporting vascular patterning and expansion through the control of cell rearrangement.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

PIK3CA mutations in vascular malformations

  • Castillo, Sandra D.
  • Baselga Torres, Eulalia
  • Graupera i Garcia-Milà, Mariona
Purpose of the review: Recently, it has been discovered that a subset of vascular malformations, of the lymphatic and venous type, are caused by oncogenic mutations in the PIK3CA gene. Now, efforts have been focused in the understanding of the molecular and cellular consequences of these mutations and the opportunities for novel targeted therapies for these diseases. Recent findings: Here, we review the latest findings in the biology of oncogenic PIK3CA mutations in the pathogenesis of vascular malformations. We focus on the recent development of in vitro and in vivo tools for the study of PIK3CA-mutant vascular malformations with special interest in preclinical models for drug testing. Also, we review the latest advances in PI3K inhibitors in the clinic and their repurposing for the treatment of lymphatic malformations (LMs) and venous malformations (VMs). Summary: Oncogenic mutations on PIK3CA causing LMs and VMs are also frequently found in epithelial cancer. Thus, fundamental research done in the cancer field during the past decades might be applied to the understanding of LMs and VMs. Likewise, repurposing PI3K pathway inhibitors that are currently in cancer clinical trials can be used as a novel strategy for the treatment of these diseases. Here, we also open a debate for the consideration of LMs and VMs as developmental tumours.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

  • Kobialka, Piotr|||0000-0003-4765-168X
  • Sabata Perez, Helena|||0000-0003-0637-0638
  • Vilalta, Odena
  • Gouveia, Leonor|||0000-0002-3825-8571
  • Angulo-Urarte, Ana|||0000-0002-8024-814X
  • Muixí, Laia
  • Zanoncello, Jasmina
  • Muñoz-Aznar, Oscar
  • Olaciregui, Nagore G.
  • Fanlo-Escudero, Lucía|||0000-0002-8364-9520
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Lavarino, Cinzia
  • Javierre, B. M.|||0000-0002-8682-6748
  • Celis, Verónica Paola
  • Rovira, Cinzia
  • López-Fernández, Susana
  • Baselga Torres, Eulàlia|||0000-0003-1086-8439
  • Mora, J.
  • Castillo, Sandra D.|||0000-0002-7007-3155
  • Graupera, Mariona|||0000-0003-4608-4185
Low-flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3ca activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K-driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Immune-interacting lymphatic endothelial subtype at capillary terminals drives lymphatic malformation

  • Petkova, Milena
  • Kraft, Marle
  • Stritt, Simon
  • Martinez-Corral, Ines
  • Ortsäter, Henrik
  • Vanlandewijck, Michael
  • Jakic, Bojana
  • Baselga Torres, Eulàlia|||0000-0003-1086-8439
  • Castillo, Sandra D.|||0000-0002-7007-3155
  • Graupera, Mariona|||0000-0003-4608-4185
  • Betsholtz, Christer
  • Mäkinen, Taija
Oncogenic mutations in PIK3CA, encoding p110α-PI3K, are a common cause of venous and lymphatic malformations. Vessel type-specific disease pathogenesis is poorly understood, hampering development of efficient therapies. Here, we reveal a new immune-interacting subtype of Ptx3-positive dermal lymphatic capillary endothelial cells (iLECs) that recruit prolymphangiogenic macrophages to promote progressive lymphatic overgrowth. Mouse model of Pik3ca-driven vascular malformations showed that proliferation was induced in both venous and lymphatic ECs but sustained selectively in LECs of advanced lesions. Single-cell transcriptomics identified the iLEC population, residing at lymphatic capillary terminals of normal vasculature, that was expanded in Pik3ca mice. Expression of pro-inflammatory genes, including monocyte/ macrophage chemokine Ccl2, inPik3ca-iLECs was associated with recruitment of VEGF-C-producing macrophages. Macrophage depletion, CCL2 blockade, or anti-inflammatory COX-2 inhibition limited Pik3ca-driven lymphangiogenesis. Thus, targeting the paracrine crosstalk involving iLECs and macrophages provides a new therapeutic opportunity for lymphatic malformations. Identification of iLECs further indicates that peripheral lymphatic vessels not only respond to but also actively orchestrate inflammatory processes.